Granules eyes first to file status, 180 days exclusivity on generic cancer drug Ruxolitinib in U.S.
Granules India seeks first mover advantage | Photo Credit: The Hindu Generic drugmaker Granules India has filed a Paragraph IV certification with the U.S. Food and Drug Administration (U.S. FDA) in connection with its abbreviated new drug application (ANDA) for Ruxolitinib Extended-Release Tablets. Based on the timing and status of its ANDA and Paragraph IV…